Decreasing postprandial C-peptide levels over time are not associated with long-term use of sulphonylurea: An observational study;La diminution à long terme du peptide-C postprandial est-elle associée au traitement au long cours par sulfonylurées ? Étude observationelle

Diabetes and Metabolism

Volumn 36, Issue 5, 2010, Pages 375-380

  Nyback Nakell A ^a   Bergstrom J ^b   Adamson, U ^a   Lins, P E ^a   Landstedt Hallin, L ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b Medical Statistics Unit   (Sweden)

Author keywords

Beta cell function; C peptide; Sulphonylurea; Treatment; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CELL FUNCTION; DISEASE DURATION; FEMALE; GENDER; GLYCEMIC CONTROL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REGRESSION ANALYSIS; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 78649445435     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.03.007     Document Type: Article

References (30)

1. UK Prospective Diabetes Study Group UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
2. Clauson P., Linnarsson R., Gottsater A., Sundkvist G., Grill V. Relationships between diabetes duration, metabolic control and beta-cell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med 1994, 11:794-801.
3. Niskanen L., Karjalainen J., Siitonen O., Uusitupa M. Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis. J Intern Med 1994, 236:263-270.
4. Shim W.S., Kim S.K., Kim H.J., Kang E.S., Ahn C.W., Lim S.K., et al. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006, 155:615-622.
5. Funakoshi S., Fujimoto S., Hamasaki A., Fujiwara H., Fujita Y., Ikeda K., et al. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 2008, 82:353-358.
6. Zangeneh F., Arora P.S., Dyck P.J., Bekris L., Lernmark A., Achenbach S.J., et al. Effects of duration of type 2 diabetes mellitus on insulin secretion. Endocr Pract 2006, 12:388-393.
7. Borg H., Gottsater A., Fernlund P., Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002, 51:1754-1762.
8. Kahn S.E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:4047-4058.
9. Leahy J.L., Bonner-Weir S., Weir G.C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992, 15:442-455.
10. Poitout V., Robertson R.P., Minireview Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
11. Alvarsson M., Sundkvist G., Lager I., Henricsson M., Berntorp K., Fernqvist-Forbes E., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003, 26:2231-2237.
12. Maedler K., Carr R.D., Bosco D., Zuellig R.A., Berney T., Donath M.Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005, 90:501-506.
13. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm f or the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
14. Albareda M., Rigla M., Rodriguez-Espinosa J., Caballero A., Chico A., Cabezas R., et al. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract 2005, 68:202-206.
15. Bo S., Cavallo-Perin P., Gentile L., Repetti E., Pagano G. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 2000, 37:125-129.
16. Ostgren C.J., Lindblad U., Ranstam J., Melander A., Rastam L. Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med 2002, 19:125-129.
17. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
18. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002, 113(Suppl. 6A):3S-11S.
19. Kosaka K., Kuzuya T., Akanuma Y., Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980, 18:23-28.
20. Garvey W.T., Olefsky J.M., Griffin J., Hamman R.F., Kolterman O.G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
21. Karvestedt L., Andersson G., Efendic S., Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med 2002, 251:307-316.
22. Tuomi T., Carlsson A., Li H., Isomaa B., Miettinen A., Nilsson A., et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999, 48:150-157.
23. Koskinen P.J., Viikari J.S., Irjala K.M. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity. Diabetes Care 1988, 11:318-322.
24. Lindstrom T., Arnqvist H.J., Ludvigsson J., von Schenck H.H. C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment. Acta Endocrinol (Copenh) 1992, 126:477-483.
25. Lencioni C., Lupi R., Del Prato S. Beta-cell failure in type 2 diabetes mellitus. Curr Diab Rep 2008, 8:179-184.
26. Hoenig M., Hall G., Ferguson D., Jordan K., Henson M., Johnson K., et al. A feline model of experimentally induced islet amyloidosis. Am J Pathol 2000, 157:2143-2150.
27. Pfutzner A., Lorra B., Abdollahnia M.R., Kann P.H., Mathieu D., Pehnert C., et al. The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2006, 8:375-384.
28. Prigeon R.L., Jacobson R.K., Porte D., Kahn S.E. Effect of sulfonylurea withdrawal on proinsulin levels. B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996, 81:3295-3298.
29. Del Guerra S., Grupillo M., Masini M., Lupi R., Bugliani M., Torri S., et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007, 23:234-238.
30. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.